Apilimod for COVID-19
Apilimod has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004
Riva et al., A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals, bioRxiv, doi:10.1101/2020.04.16.044016
Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.